Population
In vitro activated macrophages and an ex vivo/in vivo atherosclerotic plaque model of apolipoprotein E…
Design
Preclinical
Key result
Fe-PFH-PLGA/CS-DS nanoparticles selectively accumulated at SR-A sites on activated macrophages in apoE-/- mice, enabling MRI detection and LIFU-induced macrophage apoptosis.
Authors
Loading...
Preclinical SR-A–targeted PFH-DS nanoparticles enable plaque imaging and therapy; leaves open in vivo efficacy and clinical translation.
Fe-PFH-PLGA/CS-DS nanoparticles combined with low-intensity focused ultrasound show potential as multimodal probes for the specific diagnosis and targeted therapy of vulnerable atherosclerotic plaques in a preclinical model.
Ye et al. (2019) studied Atherosclerotic vulnerable plaques. Fe-PFH-PLGA/CS-DS nanoparticles combined with low-intensity focused ultrasound (LIFU) was evaluated on Phase transition, MRI enhancement, macrophage apoptosis, and selective accumulation at SR-A sites. Fe-PFH-PLGA/CS-DS nanoparticles selectively accumulated at SR-A sites on activated macrophages in apoE-/- mice, enabling MRI detection and LIFU-induced macrophage apoptosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: